Literature DB >> 20542430

Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs.

Qiang Wang1, Yanfeng Li, Chuanjun Song, Keduo Qian, Chin-Ho Chen, Kuo-Hsiung Lee, Junbiao Chang.   

Abstract

Based on the favorable antiviral profiles of 4'-substituted nucleosides, novel 1-(2'-deoxy-2'-fluoro-4'-C-ethynyl-beta-D-arabinofuranosyl)-uracil (1a), -thymine (1b), and -cytosine (2) analogs were synthesized. Compounds 1b and 2 exhibited potent anti-HIV-1 activity with IC(50) values of 86 and 1.34 nM, respectively, without significant cytotoxicity. Compound 2 was 35-fold more potent than AZT against wild-type virus, and also retained nanomolar antiviral activity against resistant strains, NL4-3 (K101E) and RTMDR. Thus, 2 merits further development as a novel NRTI drug. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20542430      PMCID： PMC2915458          DOI： 10.1016/j.bmcl.2010.05.090

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  20 in total

Review 1.  HIV inhibitors targeted at the reverse transcriptase.

Authors:  E De Clercq
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

2.  Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.

Authors:  V E Marquez; C K Tseng; H Mitsuya; S Aoki; J A Kelley; H Ford; J S Roth; S Broder; D G Johns; J S Driscoll
Journal:  J Med Chem       Date:  1990-03       Impact factor: 7.446

Review 3.  Perspectives for the chemotherapy of AIDS.

Authors:  E De Clercq
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

Review 4.  Molecular pharmacologic approaches to the treatment of AIDS.

Authors:  P S Sarin
Journal:  Annu Rev Pharmacol Toxicol       Date:  1988       Impact factor: 13.820

Review 5.  4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants.

Authors:  H Ohrui; H Mitsuya
Journal:  Curr Drug Targets Infect Disord       Date:  2001-05

6.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

7.  Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.

Authors:  Keduo Qian; Donglei Yu; Chin-Ho Chen; Li Huang; Susan L Morris-Natschke; Theodore J Nitz; Karl Salzwedel; Mary Reddick; Graham P Allaway; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

8.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity.

Authors:  J Carmichael; W G DeGraff; A F Gazdar; J D Minna; J B Mitchell
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205
View more
  2 in total

1.  Investigation of the binding between pepsin and nucleoside analogs by spectroscopy and molecular simulation.

Authors:  Zhen Li; Zhigang Li; Lingling Yang; Yuanzhe Xie; Jie Shi; Ruiyong Wang; Junbiao Chang
Journal:  J Fluoresc       Date:  2015-02-27       Impact factor: 2.217

Review 2.  FNC: An Advanced Anticancer Therapeutic or Just an Underdog?

Authors:  Daria Fayzullina; Rajesh Kumar Kharwar; Arbind Acharya; Anton Buzdin; Nicolas Borisov; Peter Timashev; Ilya Ulasov; Byron Kapomba
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.